Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 9:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–28 of 4 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Metastatic Breast Cancer to the Brain Clear all

Recruiting Phase 1Phase 2 Interventional

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

NCT06907043

View directory record Official record

Conditions: Advanced Solid Tumors
Interventions: EIK1004-001 (IMP1707-001); Drug
Lead sponsor: Eikon Therapeutics; Industry
Eligibility: 18 Years to 89 Years

Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Denver, Colorado • Lake Mary, Florida • Boston, Massachusetts + 3 more

Source: ClinicalTrials.gov public record

Updated Aug 18, 2025 · Synced May 21, 2026, 9:51 PM EDT

Completed Phase 2 Interventional Results available

Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors

NCT02038218

View directory record Official record

Conditions: Primary Brain Tumors, Metastatic Malignant Neoplasm to Brain
Interventions: 4-Demethyl-4-cholestryloxycarbonylpenclomedine; Drug
Lead sponsor: DEKK-TEC, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 3
States / cities: New Orleans, Louisiana • Lansing, Michigan • Houston, Texas

Source: ClinicalTrials.gov public record

Updated Sep 15, 2020 · Synced May 21, 2026, 9:51 PM EDT

Completed Phase 2 Interventional Results available

Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer

NCT00992602

View directory record Official record

Conditions: Central Nervous System Metastases, Leptomeningeal Metastases, Recurrent Breast Cancer, Stage IV Breast Cancer, Tumors Metastatic to Brain
Interventions: methotrexate, liposomal cytarabine, quality-of-life assessment, laboratory biomarker analysis; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only

Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Source: ClinicalTrials.gov public record

Updated Jul 6, 2017 · Synced May 21, 2026, 9:51 PM EDT

Recruiting Phase 3 Interventional

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

NCT06500455

View directory record Official record

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Stereotactic Radiosurgery; Procedure · Radiation
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older

Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 256
States / cities: Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 183 more

Source: ClinicalTrials.gov public record

Updated May 3, 2026 · Synced May 21, 2026, 9:51 PM EDT